- AU$33.90m
- -AU$33.93m
- AU$14.60m
Brief: Immutep Seeks Trading Halt
Brief: Immutep's Efti Reports Positive Initial Clinical Data
Biotech firm Immutep jumps on positive study results for cancer therapy
Brief: Immutep Announces First Clinical Data From 90mg Dosing Of Efti
Brief: Immutep Posts HY Net Loss Attributable A$21.2 Million
Brief: Immutep Receives Constructive Regulatory Feedback On TACTI-004 Registrational Trial In Metastatic Non-Small Cell Lung Cancer
Brief: Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
Brief: Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
Brief: Immutep’S Efti In Combination With Keytruda Generates Excellent Overall Survival Benefit
Australia's Immutep jumps on positive phase 2 trial results
Brief: Immutep Says Commercial Manufacturing Of Eftilagimod Alpha At 2000L Scale Granted Authorization For Clinical Trial Use
Brief: Immutep Ltd Says FY Loss After Income Tax A$39.9 Mln
Immutep's Cash And Cash Equivalent Balance As At 30 June 2023 Was About $123.4 Million
Brief: Immutep Says First Patient Dosed In Chemotherapy-Free Triple Combination Phase II Study
Brief: Immutep Secures Third U.S. Patent For Eftilagimod Alpha With Pd-1 Pathway Inhibitor
Brief: Immutep Granted United States Patent For IMP761, A First-In-Class Agonist Antibody Targeting LAG-3
Brief: Immutep Says Granted United States Patent For IMP761
Brief: Immutep Reports Final Positive Data In 2nd Line Head And Neck Squamous Cell Carcinoma
Australia's Immutep tops Ordinaries Index on positive trial data for cancer therapy